Literature DB >> 7995938

Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

L D Shultz1, P A Schweitzer, S W Christianson, B Gott, I B Schweitzer, B Tennent, S McKenna, L Mobraaten, T V Rajan, D L Greiner.   

Abstract

The scid mutation was backcrossed ten generations onto the NOD/Lt strain background, resulting in an immunodeficient stock (NOD/LtSz-scid/scid) with multiple defects in adaptive as well as nonadaptive immunologic function. NOD/LtSz-scid/scid mice lack functional lymphoid cells and show little or no serum Ig with age. Although NOD/(Lt-)+/+ mice develop T cell-mediated autoimmune, insulin-dependent diabetes mellitus, NOD/LtSz-scid/scid mice are both insulitis- and diabetes-free throughout life. However, because of a high incidence of thymic lymphomas, the mean lifespan of this congenic stock is only 8.5 mo under specific pathogen-free conditions. After i.v. injection of human CEM T-lymphoblastoid cells, splenic engraftment of these cells was fourfold greater in NOD/LtSz-scid/scid mice than in C.B17/Sz-scid/scid mice. Although C.B-17Sz-scid/scid mice exhibit robust NK cell activity, this activity is markedly reduced in both NOD/(Lt-)+/+ and NOD/LtSz-scid/scid mice. Presence of a functionally less mature macrophage population in NOD/LtSz-scid/scid vs C.B-17Sz-scid/scid mice is indicated by persistence in the former of the NOD/Lt strain-specific defect in LPS-stimulated IL-1 secretion by marrow-derived macrophages. Although C.B-17Sz-scid/scid and C57BL/6Sz-scid/scid mice have elevated serum hemolytic complement activity compared with their respective +/+ controls, both NOD/(LtSz-)+/+ and NOD/LtSz-scid/scid mice lack this activity. Age-dependent increases in serum Ig levels (> 1 micrograms/ml) were observed in only 2 of 30 NOD/LtSz-scid/scid mice vs 21 of 29 C.B-17/Sz-scid/scid animals. The multiple defects in innate and adaptive immunity unique to the NOD/LtSz-scid/scid mouse provide an excellent in vivo environment for reconstitution with human hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7995938

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  354 in total

1.  Human tumor xenografts: the good, the bad, and the ugly.

Authors:  Richard A Morgan
Journal:  Mol Ther       Date:  2012-05       Impact factor: 11.454

Review 2.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

3.  Homeostatic expansion and phenotypic conversion of human T cells depend on peripheral interactions with APCs.

Authors:  Takashi Onoe; Hannes Kalscheuer; Meredith Chittenden; Guiling Zhao; Yong-Guang Yang; Megan Sykes
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

4.  Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice.

Authors:  Deepika Rajesh; Ying Zhou; Ewa Jankowska-Gan; Drew Allan Roenneburg; Melanie L Dart; Jose Torrealba; William J Burlingham
Journal:  Hum Immunol       Date:  2010-03-26       Impact factor: 2.850

Review 5.  Human lymphohematopoietic reconstitution and immune function in immunodeficient mice receiving cotransplantation of human thymic tissue and CD34(+) cells.

Authors:  Zheng Hu; Yong-Guang Yang
Journal:  Cell Mol Immunol       Date:  2012-02-06       Impact factor: 11.530

6.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.

Authors:  Bruno Nervi; Michael P Rettig; Julie K Ritchey; Hanlin L Wang; Gerhard Bauer; Jon Walker; Mark L Bonyhadi; Ronald J Berenson; Julie L Prior; David Piwnica-Worms; Jan A Nolta; John F DiPersio
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

7.  Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.

Authors:  Na Qiao; Mao Zhang; Gheath Alatrash; Madhushree Zope; Alexander A Perakis; Pariya Sukhumalchandra; Anne V Philips; Haven R Garber; Celine Kerros; Lisa S St John; Maria R Khouri; Hiep Khong; Karen Clise-Dwyer; Leonard P Miller; Steve Wolpe; Willem W Overwijk; Jeffrey J Molldrem; Qing Ma; Elizabeth J Shpall; Elizabeth A Mittendorf
Journal:  Clin Cancer Res       Date:  2019-01-15       Impact factor: 12.531

8.  OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.

Authors:  Mark Wunderlich; Ryan A Brooks; Rushi Panchal; Garrett W Rhyasen; Gwenn Danet-Desnoyers; James C Mulloy
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

9.  VLA-5 is expressed by mouse and human long-term repopulating hematopoietic cells and mediates adhesion to extracellular matrix protein fibronectin.

Authors:  J C van der Loo; X Xiao; D McMillin; K Hashino; I Kato; D A Williams
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.

Authors:  Steve Pino; Michael A Brehm; Laurence Covassin-Barberis; Marie King; Bruce Gott; Thomas H Chase; Jennifer Wagner; Lisa Burzenski; Oded Foreman; Dale L Greiner; Leonard D Shultz
Journal:  Methods Mol Biol       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.